JP2020501508A5 - - Google Patents

Download PDF

Info

Publication number
JP2020501508A5
JP2020501508A5 JP2019513820A JP2019513820A JP2020501508A5 JP 2020501508 A5 JP2020501508 A5 JP 2020501508A5 JP 2019513820 A JP2019513820 A JP 2019513820A JP 2019513820 A JP2019513820 A JP 2019513820A JP 2020501508 A5 JP2020501508 A5 JP 2020501508A5
Authority
JP
Japan
Prior art keywords
multimer
octamer
tetramer
antibody
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019513820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020501508A (ja
Filing date
Publication date
Priority claimed from GBGB1615768.7A external-priority patent/GB201615768D0/en
Priority claimed from GBGB1713342.2A external-priority patent/GB201713342D0/en
Priority claimed from GBGB1713351.3A external-priority patent/GB201713351D0/en
Application filed filed Critical
Priority claimed from PCT/EP2017/073527 external-priority patent/WO2018050902A2/en
Publication of JP2020501508A publication Critical patent/JP2020501508A/ja
Publication of JP2020501508A5 publication Critical patent/JP2020501508A5/ja
Priority to JP2022183407A priority Critical patent/JP2023015311A/ja
Priority to JP2024209457A priority patent/JP2025029067A/ja
Pending legal-status Critical Current

Links

JP2019513820A 2016-09-15 2017-09-18 多量体、四量体および八量体 Pending JP2020501508A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022183407A JP2023015311A (ja) 2016-09-15 2022-11-16 多量体、四量体および八量体
JP2024209457A JP2025029067A (ja) 2016-09-15 2024-12-02 多量体、四量体および八量体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1615768.7 2016-09-15
GBGB1615768.7A GB201615768D0 (en) 2016-09-15 2016-09-15 Multivalent soluble TCR
GBGB1713342.2A GB201713342D0 (en) 2017-08-20 2017-08-20 Multimers & tetramers
GB1713342.2 2017-08-20
GBGB1713351.3A GB201713351D0 (en) 2017-08-21 2017-08-21 Multimers & tetramers
GB1713351.3 2017-08-21
PCT/EP2017/073527 WO2018050902A2 (en) 2016-09-15 2017-09-18 Multimers, tetramers & octamers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022183407A Division JP2023015311A (ja) 2016-09-15 2022-11-16 多量体、四量体および八量体

Publications (2)

Publication Number Publication Date
JP2020501508A JP2020501508A (ja) 2020-01-23
JP2020501508A5 true JP2020501508A5 (https=) 2020-11-05

Family

ID=60022050

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019513820A Pending JP2020501508A (ja) 2016-09-15 2017-09-18 多量体、四量体および八量体
JP2022183407A Pending JP2023015311A (ja) 2016-09-15 2022-11-16 多量体、四量体および八量体
JP2024209457A Pending JP2025029067A (ja) 2016-09-15 2024-12-02 多量体、四量体および八量体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022183407A Pending JP2023015311A (ja) 2016-09-15 2022-11-16 多量体、四量体および八量体
JP2024209457A Pending JP2025029067A (ja) 2016-09-15 2024-12-02 多量体、四量体および八量体

Country Status (4)

Country Link
US (1) US11453726B2 (https=)
EP (1) EP3512875A2 (https=)
JP (3) JP2020501508A (https=)
WO (1) WO2018050902A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020501508A (ja) 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2020018715A1 (en) * 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
EP4126933A1 (en) * 2020-03-22 2023-02-08 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021190980A1 (en) * 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
KR20250005053A (ko) * 2022-01-13 2025-01-09 인제니아 테라퓨틱스 인크. Vegf 및 tie2-결합 융합 단백질 및 그의 용도
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
CA2222055A1 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
MX336813B (es) * 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
EP1567553A2 (en) * 2002-12-03 2005-08-31 Avidex Ltd. Complexes of receptors
CA2531238C (en) 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
ATE417065T1 (de) 2004-05-19 2008-12-15 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
WO2010142551A2 (en) 2009-06-12 2010-12-16 Ablynx N.V. Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
AU2010214720A1 (en) 2009-09-24 2011-04-07 Sprywat Pty Ltd A Garden Design Method
ES2701445T3 (es) * 2010-10-15 2019-02-22 Leadartis S L Generación de complejos polipeptídicos multifuncionales y multivalentes mediante el dominio de trimerización del colágeno XVIII
CN102924600B (zh) * 2012-11-14 2013-10-30 河南大学 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
CA2942245C (en) 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
KR20180096789A (ko) 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
JP2020501508A (ja) * 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers

Similar Documents

Publication Publication Date Title
JP2020501508A5 (https=)
CN112512581B (zh) 针对cldn18.2和cd3的抗体构建体
AU2015295239B2 (en) Antibody constructs for CDH19 and CD3
IL278014B1 (en) Anti-myostatin antibodies, polypeptides containing variable fc regions and methods of use
RU2022102624A (ru) Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
TW201325612A (zh) 三倍體Ｆｃ融合蛋白及其用途
JP2020506898A5 (https=)
JP2017512063A5 (https=)
JP2019521643A5 (https=)
CN106459187A (zh) 用于抗葡萄球菌剂的吞噬细胞递送的组合物和方法
JP2019506841A5 (https=)
JP2017522903A5 (https=)
JP2019508444A5 (https=)
HRP20210635T1 (hr) Novi mutant humanog seruma albumina
JP2020532285A5 (https=)
HRP20221142T1 (hr) Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću
JP2016523910A5 (https=)
KR20160138580A (ko) Wisp1에 결합하는 항원 결합 단백질
CA3069238A1 (en) Bispecific antibodies and methods of making and using thereof
RU2015129655A (ru) Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела
JP2019511457A5 (https=)
Hayashi et al. Efficient production of recombinant cystatin C using a peptide-tag, 4AaCter, that facilitates formation of insoluble protein inclusion bodies in Escherichia coli
US20190211069A1 (en) Nucleic Acids for Single-Domain Antibodies with Thermal Stability Under Cytoplasmic Expression
JP2019518713A5 (https=)
Moricoli et al. Blocking monocyte transmigration in in vitro system by a human antibody scFv anti-CD99. Efficient large scale purification from periplasmic inclusion bodies in E. coli expression system